Successful treatment of a child with late onset T-cell post-transplant lymphoproliferative disorder/lymphoma

Kirsten M. Williams, Meghan A. Higman, Allen R. Chen, Cindy L. Schwartz, Moody Wharam, Paul Colombani, Robert J. Arceci

Research output: Contribution to journalArticlepeer-review

Abstract

We report a novel regimen for refractory post-transplant T-cell lymphoma (PTL). Our patient presented with non-Epstein-Barr virus (EBV) related, T-cell post-transplant lymphoproliferative disease (PTLD) 3.5 years after liver transplantation. Initially diagnosed as polyclonal PTLD, the disease progressed to a monoclonal, T-cell PTL that was refractory to several chemotherapy regimens but responded to a regimen consisting of fludarabine, cyclophosphamide, cytarabine, and alemtuzumab. Consolidation therapy included high-dose chemotherapy, autologous hematopoietic stem cell rescue, and radiation therapy. She remains in remission 2.5 years later. T-cell PTL is a rare disease with a poor prognosis; this regimen provides a novel, potentially curative approach for its treatment.

Original languageEnglish (US)
Pages (from-to)667-670
Number of pages4
JournalPediatric Blood and Cancer
Volume50
Issue number3
DOIs
StatePublished - Mar 1 2008

Keywords

  • Chemo-immunotherapy
  • Post-transplant lymphoproliferative disorder
  • T-cell lymphoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Successful treatment of a child with late onset T-cell post-transplant lymphoproliferative disorder/lymphoma'. Together they form a unique fingerprint.

Cite this